158 related articles for article (PubMed ID: 20655910)
1. Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders.
Hodgson RA; Bedard PJ; Varty GB; Kazdoba TM; Di Paolo T; Grzelak ME; Pond AJ; Hadjtahar A; Belanger N; Gregoire L; Dare A; Neustadt BR; Stamford AW; Hunter JC
Exp Neurol; 2010 Oct; 225(2):384-90. PubMed ID: 20655910
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression.
Hodgson RA; Bertorelli R; Varty GB; Lachowicz JE; Forlani A; Fredduzzi S; Cohen-Williams ME; Higgins GA; Impagnatiello F; Nicolussi E; Parra LE; Foster C; Zhai Y; Neustadt BR; Stamford AW; Parker EM; Reggiani A; Hunter JC
J Pharmacol Exp Ther; 2009 Jul; 330(1):294-303. PubMed ID: 19332567
[TBL] [Abstract][Full Text] [Related]
3. L-DOPA-treatment in primates disrupts the expression of A(2A) adenosine-CB(1) cannabinoid-D(2) dopamine receptor heteromers in the caudate nucleus.
Bonaventura J; Rico AJ; Moreno E; Sierra S; Sánchez M; Luquin N; Farré D; Müller CE; Martínez-Pinilla E; Cortés A; Mallol J; Armentero MT; Pinna A; Canela EI; Lluís C; McCormick PJ; Lanciego JL; Casadó V; Franco R
Neuropharmacology; 2014 Apr; 79():90-100. PubMed ID: 24230991
[TBL] [Abstract][Full Text] [Related]
4. Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice.
Smith KM; Browne SE; Jayaraman S; Bleickardt CJ; Hodge LM; Lis E; Yao L; Rittle SL; Innocent N; Mullins DE; Boykow G; Reynolds IJ; Hill D; Parker EM; Hodgson RA
Eur J Pharmacol; 2014 Apr; 728():31-8. PubMed ID: 24486705
[TBL] [Abstract][Full Text] [Related]
5. The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates.
Varty GB; Hodgson RA; Pond AJ; Grzelak ME; Parker EM; Hunter JC
Psychopharmacology (Berl); 2008 Oct; 200(3):393-401. PubMed ID: 18594798
[TBL] [Abstract][Full Text] [Related]
6. Preladenant, a novel adenosine A(2A) receptor antagonist for the potential treatment of parkinsonism and other disorders.
Salamone JD
IDrugs; 2010 Oct; 13(10):723-31. PubMed ID: 20878595
[TBL] [Abstract][Full Text] [Related]
7. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
[TBL] [Abstract][Full Text] [Related]
8. The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys.
Andersen MB; Fuxe K; Werge T; Gerlach J
Behav Pharmacol; 2002 Dec; 13(8):639-44. PubMed ID: 12478214
[TBL] [Abstract][Full Text] [Related]
9. Antagonism of the adenosine A2A receptor attenuates akathisia-like behavior induced with MP-10 or aripiprazole in a novel non-human primate model.
Bleickardt CJ; Kazdoba TM; Jones NT; Hunter JC; Hodgson RA
Pharmacol Biochem Behav; 2014 Mar; 118():36-45. PubMed ID: 24211858
[TBL] [Abstract][Full Text] [Related]
10. Adenosine 2A receptor occupancy by tozadenant and preladenant in rhesus monkeys.
Barret O; Hannestad J; Alagille D; Vala C; Tavares A; Papin C; Morley T; Fowles K; Lee H; Seibyl J; Tytgat D; Laruelle M; Tamagnan G
J Nucl Med; 2014 Oct; 55(10):1712-8. PubMed ID: 25082853
[TBL] [Abstract][Full Text] [Related]
11. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
[TBL] [Abstract][Full Text] [Related]
12. Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
Stasi MA; Minetti P; Lombardo K; Riccioni T; Caprioli A; Vertechy M; Di Serio S; Pace S; Borsini F
Eur J Pharmacol; 2015 Aug; 761():353-61. PubMed ID: 25936513
[TBL] [Abstract][Full Text] [Related]
13. Adenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders.
Kulisevsky J; Poyurovsky M
Eur Neurol; 2012; 67(1):4-11. PubMed ID: 22134373
[TBL] [Abstract][Full Text] [Related]
14. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.
Morelli M; Di Paolo T; Wardas J; Calon F; Xiao D; Schwarzschild MA
Prog Neurobiol; 2007 Dec; 83(5):293-309. PubMed ID: 17826884
[TBL] [Abstract][Full Text] [Related]
15. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
[TBL] [Abstract][Full Text] [Related]
16. An update on adenosine A2A receptors as drug target in Parkinson's disease.
Vallano A; Fernandez-Duenas V; Pedros C; Arnau JM; Ciruela F
CNS Neurol Disord Drug Targets; 2011 Sep; 10(6):659-69. PubMed ID: 21838670
[TBL] [Abstract][Full Text] [Related]
17. Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease.
Ochi M; Shiozaki S; Kase H
Neuroscience; 2004; 127(1):223-31. PubMed ID: 15219684
[TBL] [Abstract][Full Text] [Related]
18. Adenosine, adenosine A 2A antagonists, and Parkinson's disease.
Jenner P; Mori A; Hauser R; Morelli M; Fredholm BB; Chen JF
Parkinsonism Relat Disord; 2009 Jul; 15(6):406-13. PubMed ID: 19446490
[TBL] [Abstract][Full Text] [Related]
19. A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD.
Jenner P
Neurology; 2003 Dec; 61(11 Suppl 6):S32-8. PubMed ID: 14663007
[TBL] [Abstract][Full Text] [Related]
20. Adenosine A2A receptors and Parkinson's disease.
Morelli M; Carta AR; Jenner P
Handb Exp Pharmacol; 2009; (193):589-615. PubMed ID: 19639294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
